Prot# P-105-201: Phase 2 Multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant

Project: Research project

Project Details

StatusActive
Effective start/end date5/18/215/18/24

Funding

  • ICON plc (Prot# P-105-201)
  • AlloVir, Inc (Prot# P-105-201)